JP2006328074A5 - - Google Patents

Download PDF

Info

Publication number
JP2006328074A5
JP2006328074A5 JP2006171517A JP2006171517A JP2006328074A5 JP 2006328074 A5 JP2006328074 A5 JP 2006328074A5 JP 2006171517 A JP2006171517 A JP 2006171517A JP 2006171517 A JP2006171517 A JP 2006171517A JP 2006328074 A5 JP2006328074 A5 JP 2006328074A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
disease
amino acid
igf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006171517A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006328074A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2006328074A publication Critical patent/JP2006328074A/ja
Publication of JP2006328074A5 publication Critical patent/JP2006328074A5/ja
Pending legal-status Critical Current

Links

JP2006171517A 1999-01-06 2006-06-21 インシュリン様成長因子（ｉｇｆ）ｉ突然変異体 Pending JP2006328074A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11501099P 1999-01-06 1999-01-06
US17026199P 1999-12-09 1999-12-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000592321A Division JP3971108B2 (ja) 1999-01-06 2000-01-05 インシュリン様成長因子（ｉｇｆ）ｉ突然変異体

Publications (2)

Publication Number Publication Date
JP2006328074A JP2006328074A (ja) 2006-12-07
JP2006328074A5 true JP2006328074A5 (https=) 2010-09-09

Family

ID=26812755

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000592321A Expired - Lifetime JP3971108B2 (ja) 1999-01-06 2000-01-05 インシュリン様成長因子（ｉｇｆ）ｉ突然変異体
JP2006171517A Pending JP2006328074A (ja) 1999-01-06 2006-06-21 インシュリン様成長因子（ｉｇｆ）ｉ突然変異体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2000592321A Expired - Lifetime JP3971108B2 (ja) 1999-01-06 2000-01-05 インシュリン様成長因子（ｉｇｆ）ｉ突然変異体

Country Status (12)

Country Link
US (3) US6403764B1 (https=)
EP (1) EP1141014B1 (https=)
JP (2) JP3971108B2 (https=)
AT (1) ATE284415T1 (https=)
AU (1) AU762351B2 (https=)
CA (1) CA2356109C (https=)
DE (1) DE60016560T2 (https=)
DK (1) DK1141014T3 (https=)
ES (1) ES2234560T3 (https=)
IL (2) IL143866A0 (https=)
PT (1) PT1141014E (https=)
WO (1) WO2000040613A1 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875741B2 (en) * 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
US7173005B2 (en) * 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
PT1141014E (pt) 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
US7250950B2 (en) * 2001-01-29 2007-07-31 Symyx Technologies, Inc. Systems, methods and computer program products for determining parameters for chemical synthesis
US20020143725A1 (en) * 2001-01-29 2002-10-03 Smith Robin Young Systems, methods and computer program products for determining parameters for chemical synthesis and for supplying the reagents, equipment and/or chemicals synthesized thereby
US6849718B2 (en) * 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US20040048925A1 (en) * 2002-09-09 2004-03-11 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
EP1674113A1 (en) * 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
ES2408704T3 (es) 2005-01-05 2013-06-21 Biogen Idec Ma Inc. Moléculas de unión a Cripto
DK2241575T3 (en) 2005-01-07 2015-08-24 Regeneron Pharma IGF-1 fusion polypeptides and therapeutic uses thereof
TWI406870B (zh) 2005-02-21 2013-09-01 Chugai Pharmaceutical Co Ltd A method of making a protein using hamster IGF-1
CL2007001614A1 (es) * 2006-06-09 2008-08-08 Novartis Ag Polipeptido que comprende una proteina del precursor del factor de crecimiento tipo insulina, igf-1 humana, en la cual la escision del peptido e mediante una proteasa se reduce a traves de la modificacion de la proteina del precursor; y su uso para t
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
AU2007291501B2 (en) * 2006-08-31 2012-07-12 F. Hoffmann-La Roche Ag Method for the production of insulin-like growth factor-I
JP2010517023A (ja) 2007-01-25 2010-05-20 エフ．ホフマン−ラ ロシュ アーゲー 心不全の評価におけるｉｇｆｂｐ−７の使用
US20100166747A1 (en) * 2007-03-02 2010-07-01 Beltran Pedro J Methods and compositions for treating tumor diseases
JP2010529128A (ja) * 2007-06-08 2010-08-26 マサチューセッツ インスティテュート オブ テクノロジー レット症候群および他の障害の処置
MX2010010495A (es) * 2008-04-03 2010-10-15 Hoffmann La Roche Uso de variantes del factor de crecimiento similar a la insulina (igf-i) pegiladas para el tratamiento de trastornos neuromusculares.
EP2274624B1 (en) * 2008-04-03 2011-11-09 F. Hoffmann-La Roche AG Pegylated insulin-like-growth-factor assay
PL219335B1 (pl) * 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
CA2768621C (en) 2009-07-22 2016-04-05 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1) having amino acid substitution at position 59
EP2475678B1 (en) 2009-09-10 2014-10-08 Lonza Biologics Plc. Method and system for polypeptide purification
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
SG10201505217WA (en) 2010-07-09 2015-08-28 Biogen Hemophilia Inc Chimeric clotting factors
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
MX350378B (es) 2012-01-10 2017-09-05 Biogen Ma Inc Mejora del transporte de moleculas terapeuticas a traves de la barrera hematoencefalica.
JP6499080B2 (ja) 2012-12-18 2019-04-10 ノバルティス アーゲー 安定化されたインスリン様成長因子ポリペプチド
AR095527A1 (es) 2013-03-15 2015-10-21 Biogen Idec Inc Formulaciones de polipéptido fc-factor ix
CN104293766A (zh) * 2013-07-15 2015-01-21 四川农业大学 山羊IGFBP3基因cDNA编码序列克隆的方法
US20160271265A1 (en) 2013-10-02 2016-09-22 Novartis Ag Insulin-like growth factor mimetics for use in therapy
UY35874A (es) 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas
EP3098235A4 (en) 2014-01-20 2017-10-18 Hanmi Pharm. Co., Ltd. Long-acting insulin and use thereof
US20170248609A1 (en) 2014-01-27 2017-08-31 Novartis Ag Biomarkers predictive of muscle atrophy, method and use
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
AU2016215155A1 (en) 2015-02-04 2017-08-17 F. Hoffmann-La Roche Ag Tau antisense oligomers and uses thereof
EP3254104B1 (en) 2015-02-04 2021-08-25 Bristol-Myers Squibb Company Methods of selecting therapeutic molecules
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
RU2764197C1 (ru) 2016-09-23 2022-01-14 Ханми Фарм. Ко., Лтд. Аналоги инсулина с пониженной аффинностью к рецептору инсулина и их применение
AR111341A1 (es) 2017-03-23 2019-07-03 Hanmi Pharm Ind Co Ltd Un conjugado del análogo de insulina con afinidad reducida para el receptor de insulina y uso del mismo
CN117384275B (zh) * 2023-12-13 2024-03-15 北京科为博生物科技有限公司 胰岛素样生长因子突变体igf1m及其应用

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US3721252A (en) * 1971-04-01 1973-03-20 Catheter And Instr Corp Spring guide washer
US4511503A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
WO1985000831A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
JPH0720993B2 (ja) 1985-08-22 1995-03-08 グロペップ プロプライエタリー リミテッド 生長因子
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
SE8505922D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
AU627423B2 (en) 1987-04-06 1992-08-27 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them
ES2007309T3 (es) 1987-04-23 1994-11-01 Monsanto Co Secrecion del factor de crecimiento insulinoide 1 en e.coli.
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
US5470828A (en) 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
US5164370A (en) 1987-12-24 1992-11-17 Gropep Pty. Ltd. Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
ATE86496T1 (de) 1988-02-05 1993-03-15 Ciba Geigy Ag Verwendung von igf i zur herstellung eines praeparates fuer die behandlung von nierenkrankheiten.
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
AU1955388A (en) 1988-04-12 1989-11-03 Synergen, Inc. Method for potentiating and inhibiting insulin-like growth factor activity
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
CA2007886A1 (en) 1989-01-17 1990-07-17 Marvin L. Bayne Human insulin-like growth factor analogs with reduced binding to 28 k igf binding proteins and their production in yeast
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
GB8920381D0 (en) 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
ZA9010332B (en) 1989-12-22 1991-08-28 Ciba Geigy Method of reducing or preventing adverse effect of steroid therapy and compositions therefor
NZ236618A (en) 1990-01-03 1997-06-24 Ciba Geigy Ag Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5364839A (en) 1990-06-18 1994-11-15 Genetics Institute, Inc. Osteoinductive pharmaceutical formulations
US5593844A (en) * 1990-11-19 1997-01-14 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5210017A (en) * 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
SE9100099D0 (sv) 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
US5206023A (en) 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
US5206235A (en) * 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
DE69218948T2 (de) 1991-08-01 1997-07-31 Auckland Uniservices Ltd IGF-I zur Verbesserung der neuronale Lage
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
TW267102B (https=) 1992-03-13 1996-01-01 Ciba Geigy
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
ES2140463T3 (es) 1992-06-12 2000-03-01 Cephalon Inc Prevencion y tratamiento de la neuropatia periferica.
GB9217696D0 (en) 1992-08-20 1992-09-30 Agricultural & Food Res Use of specific binding molecules
US5273961A (en) 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
US5342763A (en) * 1992-11-23 1994-08-30 Genentech, Inc. Method for producing polypeptide via bacterial fermentation
DK0600372T3 (da) * 1992-12-02 1997-08-11 Hoechst Ag Fremgangsmåde til fremstilling af proinsulin med korrekt forbundne cystinbroer.
WO1994016722A1 (en) 1993-01-25 1994-08-04 The Beth Israel Hospital Association Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties
CA2154078A1 (en) 1993-01-29 1994-08-04 George N. Cox Wound healing composition
US5457109A (en) 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
HU224345B1 (hu) 1993-12-23 2005-08-29 Novo Nordisk A/S. Növekedési hormont felszabadító tulajdonságú peptidek, ezeket hatóanyagként tartalmazó gyógyszerkészítmények és alkalmazásuk
JP3759748B2 (ja) 1993-12-23 2006-03-29 ノボ ノルディスク アクティーゼルスカブ 成長ホルモン放出性を有する化合物
US5597700A (en) 1994-04-28 1997-01-28 California Research, Llc Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method
US5444047A (en) * 1994-06-16 1995-08-22 Dipasquale; Gene Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I
SE9402331D0 (sv) 1994-07-01 1994-07-01 Pharmacia Ab New use
SE9402370D0 (sv) 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
HRP940432B1 (en) 1994-08-05 2003-10-31 Pliva Pharm & Chem Works Dna sequences encoding biosynthetic insulin precursors and process for preparation of insulin
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5798337A (en) 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
SE9501472D0 (sv) 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I
US5622932A (en) 1995-05-05 1997-04-22 Eli Lilly And Company IGF-1 superagonists
US5565428A (en) 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US5741776A (en) 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
JP3576170B2 (ja) 1995-05-26 2004-10-13 セラテクノロジーズ・インコーポレーテッド 生物学的活性が増加したキメラ脂肪体プロｇｒｆ類似体
TR199701526T1 (xx) 1995-06-07 1998-03-21 Glaxo Group Limited Bir trombopoietin resept�r�ne ba�lanan peptitler ve bile�ikler.
WO1996040189A1 (en) 1995-06-07 1996-12-19 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5958872A (en) 1996-04-01 1999-09-28 Apoptosis Technology, Inc. Active survival domains of IGF-IR and methods of use
EP0854884A1 (en) 1996-04-17 1998-07-29 Neurocrine Biosciences, Inc. Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
CA2265972A1 (en) 1996-09-16 1998-03-26 Philip D. Acott Use of igf-i for the treatment of polycystic kidney disease and related indications
EP0938497B1 (en) 1996-11-06 2007-02-28 Genentech, Inc. Constrained helical peptides and methods of making same
EP0965596A1 (en) 1996-12-27 1999-12-22 Daiichi Pharmaceutical Co., Ltd. Method for elevating the concentration of free insulin-like growth factor
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
ZA984697B (en) 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
DE19757250A1 (de) 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung
AU3548999A (en) 1998-04-03 1999-10-25 Chiron Corporation Use of igfi for treating articular cartilage disorders
WO2000020023A2 (en) 1998-10-02 2000-04-13 Celtrix Pharmaceuticals, Inc. Null igf for the treatment of cancer
AU6515499A (en) 1998-10-16 2000-05-08 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
PT1141014E (pt) * 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
JP2002535967A (ja) * 1999-01-06 2002-10-29 ジェネンテック・インコーポレーテッド インシュリン様成長因子（ｉｇｆ）ｉ変異体
WO2000069901A2 (en) 1999-05-19 2000-11-23 Xencor, Inc. Proteins with insulin-like activity useful in the treatment of diabetes
JP2009542719A (ja) 2006-07-06 2009-12-03 モレキュラー ロジックス，インコーポレイテッド インスリン様成長因子−ｉレセプターアンタゴニスト

Similar Documents

Publication Publication Date Title
JP2006328074A5 (https=)
CN103702672B (zh) 用于预防和治疗糖尿病、低血糖症及相关病症的胰岛素和铬组合物
US9006185B2 (en) Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
CN103732618B (zh) 新型泌酸调节肽衍生物和包含该泌酸调节肽衍生物的用于治疗肥胖的药物组合物
JP2010524928A5 (https=)
ES3023833T3 (en) Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
JP2019534248A (ja) アミリン類似体
JP2017537894A (ja) Ｇｌｐ−１ｒおよびｇｌｐ−２ｒ二重アゴニスト活性を有する組成物及びペプチド
CN104010652A (zh) 超浓缩的速效胰岛素类似物制剂
DK1768689T3 (en) Compositions and methods for treating cardiovascular disease
JP2014515747A5 (https=)
US7713533B2 (en) Active complex of α-lactalbumin (HAMLET) and cofactor
JPH08500827A (ja) 異化症状および全身性組織創傷の全身的治療方法
Kyhl et al. Lack of effect of prolonged treatment with liraglutide on cardiac remodeling in rats after acute myocardial infarction
WO2019095685A1 (zh) 一种功能多肽及其在制备防治肺纤维化药物中的应用
Kielstein et al. The past, presence and future of ADMA in nephrology
CN109890400B (zh) 包含蛋白磷酸酶1抑制肽的血管疾病治疗用组合物
Lipkin et al. Enhanced natriuretic response to neutral endopeptidase inhibition in patients with moderate chronic renal failure
Papadimitriou et al. Mineralocorticoid deficiency in post-operative cerebral salt wasting.
CN101258163B (zh) Glp-1药物组合物
WO2005110394A1 (ja) 糖尿病治療薬
JP2019520341A (ja) 代謝疾患を治療する組成物と方法
US20250387390A1 (en) Methods for treating fibrosis using pkm2 activators
IL315941A (en) Uses of farnesoid x receptor agonists
JP6094485B2 (ja) ビリルビン排泄促進剤